Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 10/20 | 0.53 |
| ▸ | TK1 | P04183 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26034606 | 1.00 | TK2 (0.53) | TK2TK1CYP2C9KMT2AMAPT | |
| SCHEMBL24322118 | 0.90 | TYMP (0.54) | TK2TK1TYMP | |
| SCHEMBL26035287 | 0.89 | TSHR (0.44) | TK2TK1CYP2C9KMT2AMAPT | |
| SCHEMBL24205081 | 0.88 | TSHR (0.45) | TK2TK1CYP2C9KMT2AMAPT | |
| SCHEMBL16614260 | 0.87 | LMNA (0.50) | TK2TK1TYMP | |
| SCHEMBL24205266 | 0.85 | CYP2C9 (0.47) | TK2TK1CYP2C9KMT2AMAPT | |
| SCHEMBL26035300 | 0.85 | LMNA (0.50) | TK2TK1CYP2C9KMT2AMAPT | |
| SCHEMBL26035299 | 0.82 | TK2 (0.53) | TK2TK1CYP2C9KMT2AMAPT | |
| SCHEMBL26034607 | 0.82 | TK2 (0.53) | TK2TK1CYP2C9KMT2AMAPT | |
| SCHEMBL26034665 | 0.82 | TK2 (0.53) | TK2TK1CYP2C9KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | TK2 3617/4885TK1 2438/4885CYP2C9 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.